PHO13 Antibody

What is PHO13 and why is it important for metabolic research?

PHO13 encodes a phosphatase enzyme primarily studied in Saccharomyces cerevisiae (baker's yeast). It functions as a metabolic proofreading enzyme that dephosphorylates potentially toxic metabolites such as 2-phosphoglycolate and 2-phospho-L-lactate. These metabolites can potently inhibit key glycolytic enzymes including triosephosphate isomerase and phosphofructokinase, making PHO13's clearance function vital for cellular survival and metabolic functioning . The importance of PHO13 extends to engineered strains where its deletion (Δpho13) has been shown to improve xylose fermentation capability, a critical factor for biofuel production and other biotechnological applications .

What are the primary applications of PHO13 antibodies in research?

PHO13 antibodies serve several crucial research functions:

• Protein detection and quantification in western blots and immunoblotting

• Immunoprecipitation for protein-protein interaction studies

• Immunofluorescence for subcellular localization analysis

• Chromatin immunoprecipitation (ChIP) when studying transcriptional regulation

• Validation of gene knockout or knockdown experiments (Δpho13 strains)

These applications are essential for researchers investigating metabolic regulation, particularly in studies examining the non-oxidative pentose phosphate pathway (PPP) and glycolysis interactions .

How does PHO13 function relate to transcriptional regulation in metabolic pathways?

Deletion of PHO13 (Δpho13) causes significant transcriptional changes, particularly the upregulation of genes involved in the non-oxidative pentose phosphate pathway (PPP) and downregulation of glycolytic genes . This transcriptional reprogramming contributes to improved xylose fermentation in engineered yeast strains. The relationship appears to involve phosphatase activity on sedoheptulose-7-phosphate, as evidenced by reduction of its dephosphorylation product in Δpho13 strains . The detailed molecular mechanism remains under investigation, making PHO13 antibodies valuable tools for studying these transcriptional and metabolic regulatory networks.

What are the optimal methods for generating PHO13 knockout strains for antibody validation?

When generating PHO13 knockout (Δpho13) strains for antibody validation, researchers should consider several methodological approaches:

• Homologous recombination strategy: Integration of marker cassettes (such as human dihydrofolate reductase, hDHFR) can be used, though specific integration should be confirmed by PCR as non-specific integration has been observed in similar systems .

• Conditional knockdown approach: For essential genes similar to PHO13, a regulatable fluorescent affinity (RFA) tag can be employed, where protein stability is conditional to binding of a small molecule (such as trimethoprim). This approach should be validated by PCR to confirm correct insertion .

• CRISPR-Cas9 system: For precise genome editing, though not explicitly mentioned in the search results, this represents a modern alternative to traditional knockout methods.

Following strain generation, validation with PHO13 antibodies via western blotting is crucial to confirm complete protein elimination or conditional depletion.

What controls should be included when using PHO13 antibodies in immunoblotting experiments?

When conducting immunoblotting with PHO13 antibodies, the following controls are essential:

• Positive control: Wild-type strain expressing PHO13 at normal levels

• Negative control: Validated Δpho13 strain showing absence of the protein

• Loading control: Detection of a constitutively expressed protein such as phosphoglycerate kinase (Pgk1), as demonstrated in similar experimental setups

• Specificity control: Pre-incubation of the antibody with purified PHO13 protein to confirm binding specificity

• Cross-reactivity assessment: Testing against similar phosphatases to ensure specificity

Cell lysis should be performed with appropriate buffers containing protease inhibitors (such as complete Protease Inhibitor Cocktail) and N-ethylmaleimide to preserve protein integrity, followed by separation on 4-12% gradient gels (such as NuPage gels) .

How can RNA-seq data be used to validate PHO13 antibody specificity and function?

RNA-seq analysis provides powerful validation for PHO13 antibody specificity and function through multiple approaches:

• Transcriptional signature verification: RNA-seq can confirm the expected transcriptional changes in Δpho13 strains, particularly upregulation of PPP genes and downregulation of glycolytic genes . This transcriptional signature serves as a functional validation for antibodies used in confirming the knockout.

• Correlation analysis: By correlating protein levels detected by PHO13 antibodies with mRNA levels from RNA-seq, researchers can validate antibody performance across various experimental conditions.

• Strain validation: RNA-seq can confirm the genetic status of strains used for antibody validation by verifying the absence of PHO13 transcripts in knockout models.

• Downstream effects: RNA-seq can identify downstream genes affected by PHO13 deletion, providing targets for further antibody-based protein studies to confirm functional relationships.

For robust analysis, RNA should be extracted from exponentially growing cells (approximately 0.5 mg) of both control and Δpho13 strains, followed by standard RNA-seq protocols .

How can PHO13 antibodies be used to study metabolic proofreading mechanisms?

PHO13 antibodies can be employed in sophisticated studies of metabolic proofreading through several advanced techniques:

• Protein complex identification: Immunoprecipitation with PHO13 antibodies followed by mass spectrometry can identify interaction partners involved in metabolic proofreading pathways.

• Dynamic regulation studies: Combining PHO13 antibodies with pulse-chase experiments can reveal the temporal dynamics of metabolic proofreading in response to cellular stresses.

• Substrate profiling: Using PHO13 antibodies to purify the native enzyme for in vitro activity assays can help identify the full spectrum of metabolites subject to proofreading, beyond the known 2-phosphoglycolate and 2-phospho-L-lactate substrates .

• Structural studies: PHO13 antibodies can aid in protein crystallization and structure determination by stabilizing specific conformations, potentially revealing mechanism-related structural changes.

• In vivo phosphatase activity: Combining PHO13 antibody-based detection with metabolomic analysis can reveal how this enzyme prevents accumulation of toxic phosphorylated metabolites under various physiological conditions.

The essential nature of metabolic proofreading for cellular survival makes these studies particularly valuable, as they can identify potential intervention points in pathogens where this process might be disrupted .

What approaches can resolve contradictory data regarding PHO13 substrate specificity using antibody-based techniques?

Resolving contradictory findings regarding PHO13 substrate specificity (such as conflicting reports about preference for 2-phospho-D-lactate versus 2-phospho-L-lactate ) requires sophisticated antibody-based approaches:

• Conformational-specific antibodies: Developing antibodies that recognize PHO13 in different substrate-bound states can help discriminate between binding preferences.

• Proximity labeling: Combining PHO13 antibodies with techniques like BioID or APEX2 can identify proximal metabolites in vivo, clarifying actual substrate interactions.

• Single-molecule studies: Using PHO13 antibodies for single-molecule pulldowns followed by FRET analysis can reveal dynamic substrate binding events.

• Competitive binding assays: Immobilized PHO13 antibodies can be used to study competitive binding of different potential substrates, helping to establish relative affinities.

• Substrate-induced conformational changes: Antibodies recognizing specific PHO13 epitopes can detect conformational changes upon binding different substrates, providing indirect evidence for substrate preference.

These approaches can help reconcile conflicting findings, such as those reported regarding PfPGP's preference for different stereoisomers of phospholactate .

How can PHO13 antibodies be integrated with biosensor technologies to map intracellular enzyme activity?

Integration of PHO13 antibodies with biosensor technologies represents a cutting-edge approach to mapping intracellular enzyme activity with high spatial and temporal resolution:

• Nanoscale H2O2 distribution mapping: PHO13 antibodies can be combined with H2O2 biosensors like HyPer7 to study potential metabolic hotspots where PHO13 activity might regulate redox homeostasis . This can reveal fine-grained differences in enzymatic activity beyond traditional compartment-level analyses.

• FRET-based activity sensors: PHO13 antibody fragments (Fab or scFv) can be incorporated into FRET-based biosensors that change conformation upon substrate processing, allowing real-time monitoring of phosphatase activity.

• Multi-modal imaging: Combining PHO13 antibodies with both fluorescent tags and electron microscopy-compatible labels can provide correlated light and electron microscopy data on enzyme localization relative to metabolic activity zones.

• Protein-tagging libraries: Similar to the HyPer7/SypHer7 fusion protein libraries described , PHO13 antibody epitope tagging can generate libraries of protein-specific biosensors to study context-dependent enzymatic activity.

• Dynamic compartment analysis: PHO13 antibodies can help identify potential membraneless condensates where the enzyme might be concentrated, correlating with metabolic activity patterns revealed by biosensors.

This integration provides deeper understanding of how PHO13's metabolic proofreading function is spatially and temporally regulated within cells.

What are the common causes of non-specific binding when using PHO13 antibodies and how can they be addressed?

Non-specific binding is a common challenge with PHO13 antibodies that can be systematically addressed:

• Cross-reactivity with similar phosphatases: PHO13 belongs to the haloacid dehalogenase superfamily (HADSF), whose members show considerable activity toward similar substrates including nucleotide monophosphates and phosphorylated co-factors . Validate antibody specificity against purified related enzymes.

• Protein solubility issues: Expression and purification difficulties have been reported for PfPGP (PHO13 homolog), where the protein was found completely in the insoluble fraction . Consider:

  • Using protein solubility prediction software like PROSOII to identify more soluble homologs

  • Optimizing expression conditions (temperature, induction time)

  • Adding solubility tags or fusion partners

• Sample preparation artifacts: Ensure complete cell lysis using bead beating in appropriate buffers containing protease inhibitors and N-ethylmaleimide .

• Blocking optimization: Test different blocking agents (BSA, milk, commercial blockers) at various concentrations and incubation times to minimize background.

• Secondary antibody cross-reactivity: Perform control experiments with secondary antibody alone to identify potential direct binding to sample components.

• Validation in knockout models: Always validate antibody specificity using confirmed Δpho13 strains as negative controls .

How can sequence variations in PHO13 homologs across species affect antibody selection and experimental design?

Sequence variations in PHO13 homologs across species present important considerations for antibody selection and experimental design:

• Epitope conservation analysis: Before selecting antibodies, researchers should align PHO13 sequences from target species to identify conserved and variable regions. Antibodies targeting highly conserved epitopes offer broader cross-species reactivity.

• Solubility considerations: As observed with PfPGP (from P. falciparum) versus PbPGP (from P. berghei), homologs can differ significantly in solubility properties . This affects not only antibody production but also the design of immunoprecipitation and pulldown experiments.

• Functional domain targeting: Antibodies targeting catalytic domains versus regulatory regions will provide different information about enzyme function across species.

• Species-specific validation: Each PHO13 homolog antibody should be validated in the specific organism of interest, as demonstrated by the different approaches needed for PfPGP versus PbPGP .

• Custom antibody development: For poorly conserved regions or species-specific research questions, custom antibody development against synthetic peptides from the species of interest may be necessary.

This careful consideration of homology ensures antibody-based experiments yield interpretable and biologically relevant results across different model organisms.

How can machine learning approaches improve PHO13 antibody specificity and experimental design?

Machine learning approaches offer promising avenues for enhancing PHO13 antibody specificity and experimental design:

• Epitope prediction and optimization: Machine learning models trained on antibody-epitope interaction data can predict optimal epitopes for PHO13 antibody generation with maximal specificity and minimal cross-reactivity.

• Binding mode identification: Similar to the approach described for antibody specificity inference , computational models can identify distinct binding modes for PHO13 antibodies, enabling the design of variants with customized specificity profiles for different research applications.

• Experimental condition optimization: Machine learning can predict optimal conditions for antibody-based assays by analyzing historical experimental data, reducing the need for extensive optimization experiments.

• Cross-reactivity prediction: Models trained on protein sequence and structure data can predict potential cross-reactivity with other phosphatases, allowing researchers to select or design antibodies that minimize unwanted interactions.

• Automated image analysis: For PHO13 immunofluorescence experiments, machine learning algorithms can improve detection sensitivity and quantification accuracy, particularly in challenging samples with high background or low signal.

As demonstrated in recent antibody research, biophysics-informed models can disentangle multiple binding modes and enable the generation of antibodies with precise specificity profiles not present in initial libraries .

What are the implications of PHO13's role in metabolic regulation for developing targeted research tools?

PHO13's central role in metabolic regulation presents opportunities for developing sophisticated research tools:

These implications highlight the intersection of basic metabolic research with potential biotechnological and biomedical applications, emphasizing the value of developing precise PHO13-targeted research tools.

How might developments in structural biology techniques enhance PHO13 antibody applications?

Recent advances in structural biology offer exciting possibilities for enhancing PHO13 antibody applications:

• Cryo-EM studies: High-resolution cryo-electron microscopy can reveal PHO13 structure in complex with antibodies, providing insights into epitope recognition and potentially revealing conformational changes associated with substrate binding.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): When combined with PHO13 antibodies, HDX-MS can map dynamic regions of the protein involved in substrate recognition and catalysis, informing better antibody design.

• AlphaFold2 and protein structure prediction: Computational predictions of PHO13 structure can guide rational antibody design targeting specific functional domains or conformational states.

• Single-particle tracking: Advanced microscopy combined with PHO13 antibody fragments can enable tracking of individual enzyme molecules within cells, revealing dynamic behaviors not captured by traditional methods.

• Nanobody development: The smaller size and unique binding properties of nanobodies derived from PHO13 antibodies could enable access to structured regions inaccessible to conventional antibodies, particularly for intracellular applications.

These structural biology approaches can transform PHO13 antibodies from simple detection tools into sophisticated probes of enzyme function and dynamics in complex cellular environments.